175696-70-5

Usage

Uses

Used in Pharmaceutical Industry:
(3-Pyrrolidin-1-ylphenyl)methylamine is used as a chemical intermediate for the development of pharmaceuticals, potentially targeting the central nervous system due to the presence of the phenylmethylamine structure, which is known to have neurological effects.
Used in Organic Synthesis:
In the field of organic synthesis, (3-Pyrrolidin-1-ylphenyl)methylamine serves as a building block for the creation of more complex organic compounds, leveraging its amine functionality for further chemical reactions and the introduction of novel molecular structures.
Used in Research:
(3-Pyrrolidin-1-ylphenyl)methylamine is utilized in research settings to explore its chemical properties and potential interactions with biological systems, contributing to a deeper understanding of phenylmethylamine compounds and their effects on the central nervous system.

InChI:InChI=1/C11H16N2/c12-9-10-4-3-5-11(8-10)13-6-1-2-7-13/h3-5,8H,1-2,6-7,9,12H2

Upstream product

• 2237-30-1 m-cyanoaniline 
• 828242-06-4 tert-butyl N-[(3-pyrrolidin-1-ylphenyl)methyl]carbamate 
• 263351-43-5 tert-butyl N-[(3-iodophenyl)methyl]carbamate 
• 766-84-7 3-chloro-benzonitrile 
• 175696-73-8 3-(pyrrolidin-1-yl)benzonitrile 

Downstream Products

• 1028338-17-1 4-chloro-6-(3-pyrrolidin-1-yl-benzylamino)-2H-phthalazin-1-one 
• 1092067-86-1 C₃₄H₄₀Cl₂N₆O₂ 
• 1590397-58-2 2-(4-fluoro-N-isopropylphenylsulfonamido)-N-(3-(pyrrolidin-1-yl)benzyl)acetamide 
• 828242-06-4 tert-butyl N-[(3-pyrrolidin-1-ylphenyl)methyl]carbamate 

Relevant academic research and scientific papers

A State-of-the-Art Heterogeneous Catalyst for Efficient and General Nitrile Hydrogenation

Cobalt-doped hybrid materials consisting of metal oxides and carbon derived from chitin were prepared, characterized and tested for industrially relevant nitrile hydrogenations. The optimal catalyst supported onto MgO showed, after pyrolysis at 700 °C, magnesium oxide nanocubes decorated with carbon-enveloped Co nanoparticles. This special structure allows for the selective hydrogenation of diverse and demanding nitriles to the corresponding primary amines under mild conditions (e.g. 70 °C, 20 bar H2). The advantage of this novel catalytic material is showcased for industrially important substrates, including adipodinitrile, picolinonitrile, and fatty acid nitriles. Notably, the developed system outperformed all other tested commercial catalysts, for example, Raney Nickel and even noble-metal-based systems in these transformations.

Cobalt pincer complexes for catalytic reduction of nitriles to primary amines

Various cobalt pincer type complexes 1-6 were applied for the catalytic hydrogenation of nitriles to amines. Among these, catalyst 4 is the most efficient, allowing the reduction of aromatic as well as aliphatic nitriles in moderate to excellent yields.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

SUBSTITUTED SULFONAMIDE COMPOUNDS

The invention is concerned with the compounds of formula (I), and salts thereof, wherein X, Y, Z, R1, R2, R3, R3, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS

Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R

The antiinfluenza activity of pyrrolo[2,3-d]pyrimidines

From a group of pyrrolo[2,3-d]pyrimidine compounds that have been screened against influenza virus, one derivative, 4-(3-piperidinyl benzylamino)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (9), has shown promising activity against both the A and B strains. The